Literature DB >> 86447

Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer.

F Pannuti, A Martoni, A R Di Marco, E Piana, F Saccani, G Becchi, G Mattioli, F Barbanti, G A Marra, W Persiani, L Cacciari, F Spagnolo, D Palenzona, G Rocchetta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 86447     DOI： 10.1016/0014-2964(79)90097-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  15 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.

Authors:  A D Stockdale; A Y Rostom
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

3.  A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer.

Authors:  H L Parnes; J S Abrams; N S Tchekmedyian; N Tait; J Aisner
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

4.  On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.

Authors:  E Petru; D Schmähl
Journal:  Klin Wochenschr       Date:  1987-10-15

5.  High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.

Authors:  M De Lena; C Brambilla; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 6.  Deciphering the divergent roles of progestogens in breast cancer.

Authors:  Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

7.  Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment.

Authors:  W Scheithauer; C Zielinksi; H Ludwig
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

Review 8.  Endocrine therapy for advanced breast cancer: a review.

Authors:  H B Muss
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

9.  Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases.

Authors:  J Jääskeläinen; E Laasonen; J Kärkkäinen; M Haltia; H Troupp
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

10.  Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.

Authors:  C M Camaggi; E Strocchi; M Giovannini; B Angelelli; B Costanti; E Zebini; P Ferrari; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.